The Science Behind Our Integrated Approach
A groundbreaking Mayo Clinic study reveals that combining hormone therapy with GLP-1 medications delivers significantly better weight loss outcomes for postmenopausal women.
Compared to GLP-1 medication alone
Average loss in hormone therapy group
Nearly double the non-HRT group (24%)
Study Overview
Research Team
Led by Maria Daniela Hurtado Andrade, MD, PhD of the Mayo Clinic in Jacksonville, Florida, and colleagues. The study was a retrospective cohort analysis with propensity score matching.
Key Findings
The study revealed significant advantages for postmenopausal women who combined hormone therapy with tirzepatide (Zepbound) for weight management.
Superior Weight Loss
Women using hormone therapy lost an average of 19.2% of their body weight, compared to 14% for those not using hormone therapy—a statistically significant difference (P=0.0023).
Cardiometabolic Improvements
Beyond weight loss, hormone therapy users showed additional improvements in key cardiometabolic markers that are critical for long-term health.
Favorable Side Effect Profile
Interestingly, hormone therapy users experienced fewer gastrointestinal side effects (30%) compared to non-users (43%). Other adverse events were similar between groups, including headache (4%), hypoglycemia (3%), fatigue (1%), and urticaria (1%).
Expert Commentary
"Women in the hormone therapy group lost 35% more body weight than those in the no hormone therapy group and showed notable improvements in key cardiometabolic parameters, supporting a potential enhancing effect of hormone therapy on tirzepatide's therapeutic effect."
"These findings add complexity to sex differences in treatment with GLP-1 receptor agonists and warrant stratification in randomized controlled trials, not only by sex, but also by menopausal stage."
Why This Matters
Menopause is a critical window that can dramatically increase cardiovascular disease risk in women with obesity. This research emphasizes the importance of personalized approaches.
The Biological Explanation
The researchers noted that while the improvements likely stem from greater weight loss, hormone therapy may also exert independent beneficial effects due to the well-established physiological actions of estrogen on:
Read the Original Research
Access the full peer-reviewed study published in Lancet Obstetrics, Gynaecology, & Women's Health.
Citation: Castaneda R, et al. "The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study." Lancet Obstet Gynaecol Womens Health 2026.
Our Integrated Approach
At Lehigh Valley Wellness, we're among the first practices to offer this evidence-based combination therapy for optimal weight loss results.
Weight Loss + Hormone Therapy Program
$299/month after $149 Initial Evaluation • $50 deposit required
Ready to Start Your Journey?
Schedule a consultation today to discuss your health goals with Stephen McCarthy, PA-C.